Aficamten vs Metoprolol: MAPLE Trial | AHA | JACC
Автор: American College of Cardiology
Загружено: 2025-11-09
Просмотров: 201
In this JACC publication, JACC deputy editor John A. Spertus, MD, FACC, speaks with lead author Michael Nassif, MD, FACC, discussing the AHA Featured Science Maple Trial. In symptomatic obstructive hypertrophic cardiomyopathy, greater health status improvements were seen after 24 weeks of aficamten (cardiac myosin inhibitor) than metoprolol, with a mean difference in Kansas City Cardiomyopathy Questionnaire Overall Summary score of +7.8 points (P less than 0.001) and Seattle Angina Questionnaire Summary score of +4.6 points (P=0.063). Very large clinical improvements (≥20 points) were much more common with aficamten treatment than with metoprolol (38.6% vs. 18.4%), suggesting a number needed to treat of 4.9 (95% CI 3.0, 13.9) for one participant to feel much better with aficamten than metoprolol. #JACC #jaccjournals #aha25
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке:
